Calquence is under clinical development by AstraZeneca and currently in Phase II for Graft Versus Host Disease (GVHD).

NEXI-001 is under clinical development by NexImmune and currently in Phase II for Myelodysplastic Syndrome. According to GlobalData, Phase II drugs for Myelodysplastic Syndrome have a 30% phase ...

Amigo definición Bayer's new anticancer drug for all types of cancer has been approved for clinical trials in China How is the implementation of hepa ...